Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines, in collaboration with the BeOne Care Foundation and The Max Foundation, has renewed their partnership until 2028. This initiative aims to improve access to BRUKINSA® for patients with chronic lymphocytic leukemia in low- and middle-income countries. The partnership emphasizes the importance of addressing healthcare inequalities in cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Renewal of partnership through 2028 enhances access to treatment.
  • Focus on low- and middle-income countries addresses healthcare disparities.
  • Collaboration with reputable organizations strengthens impact.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with

Frequently Asked Questions

What is BRUKINSA® used for?

BRUKINSA® is used for the treatment of chronic lymphocytic leukemia (CLL).

Who are the partners in this initiative?

The partners are BeOne Medicines, BeOne Care Foundation, and The Max Foundation.

How long is the partnership renewed for?

The partnership has been renewed through 2028.

What regions will benefit from this partnership?

The partnership aims to expand access in low- and middle-income countries.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines BRUKINSA chronic lymphocytic leukemia The Max Foundation low-income countries
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →